Select Language:
A pharmaceutical company in Israel has partnered with NeuroGen Pharma to expand the availability of the migraine medication Ajovy across China. NeuroGen Pharma will obtain exclusive rights to commercialize Ajovy within mainland China, including licensing the associated patents and trademarks. The company will also oversee obtaining the necessary marketing approval for the product in the region.
Ajovy is designed to help patients manage long-term migraine symptoms. It received approval from the U.S. Food and Drug Administration for adult use in 2018 and was granted European authorization the following year.
The CEO of NeuroGen Pharma expressed enthusiasm about the strategic partnership, stating, “We are very pleased to establish this collaboration. We plan to leverage our local expertise and networks to bring Ajovy closer to clinical practice and patient needs in China, ensuring wider and more sustainable access to this innovative treatment.”
The general manager of the pharmaceutical company highlighted that Ajovy exemplifies the company’s ongoing commitment to innovation and long-term investment in neurological therapies. He noted that Ajovy is now available in over 45 countries and has become the leading preventive injection therapy for migraines in many markets.
An estimated 185 million people in China suffer from migraines, according to recent studies.
Founded in 1901, the pharmaceutical company is focusing on transforming into a leading global biopharmaceutical enterprise, building on its strong foundation in generics and biosimilars.
NeuroGen Pharma is a biopharmaceutical firm that specializes in neurological treatments. It was established through a collaboration between Singapore’s CBC Group and the United Arab Emirates’ Mubadala Investment Company. In 2024, it acquired five established brands in neurology and allergy treatments from Union Chimique Belge in China, along with a manufacturing facility in Zhuhai.
ChatGPT
Perplexity
Gemini AI
Grok AI
